Health
Bayer Eyes Wider Use for Prostate Cancer Drug
- Nubeqa has already seen fast growth since its launch in 2019
- Drugmaker is trying to offset patent cliff from another drug
This article is for subscribers only.
Bayer AG’s fast-selling prostate cancer drug reduced the risk of the disease progressing in data that could see it receive approval for wider use.
Nubeqa alongside androgen deprivation therapy reduced the risk of death or cancer progression by 46% compared with just receiving androgen deprivation therapy, according to full data from a late stage study. If approval is secured it could mean doctors could prescribe the drug for patients both with and without chemotherapy, expanding treatment options.